What Is Tirzepatide?
Quick Answer
Overview GLP-2 Analog (Teduglutide; ALX-0600) is a 33-amino-acid recombinant analog of human glucagon-like peptide-2 (GLP-2) originally engineered by Drucker and colleagues to extend the very short circulating half-life of native GLP-2 (~7 minutes) by substituting glycine for alanine at position 2, ...
Overview
GLP-2 Analog (Teduglutide; ALX-0600) is a 33-amino-acid recombinant analog of human glucagon-like peptide-2 (GLP-2) originally engineered by Drucker and colleagues to extend the very short circulating half-life of native GLP-2 (~7 minutes) by substituting glycine for alanine at position 2, the canonical dipeptidyl-peptidase-IV (DPP-IV) cleavage site. The single Ala²Gly substitution renders the peptide resistant to N-terminal proteolysis while preserving full agonist activity at the GLP-2 receptor (GLP-2R), extending the in vivo functional half-life by roughly an order of magnitude in preclinical pharmacokinetic studies.[1][2]
The native GLP-2 peptide is co-secreted with GLP-1 from intestinal L-cells in response to luminal nutrients and acts in a paracrine fashion on neighboring enterocytes, sub-epithelial fibroblasts, and enteric neurons expressing the Gαs-coupled GLP-2 receptor. The biological signature studied in preclinical models centers on intestinotrophic readouts: increased villus height, increased crypt depth, expanded small-bowel mucosal mass, and changes in nutrient-transport capacity in rodent and large-animal models of small-bowel resection and parenteral-nutrition dependence.[3][4]
Discovery and design rationale
Drucker and colleagues at the University of Toronto first reported GLP-2's intestinotrophic activity in 1996 after observing dramatic small-bowel hyperplasia in mice bearing GLP-2-secreting glucagonoma xenografts. Mapping the active sequence to the proglucagon-derived 33-mer launched a structure-activity program that identified the Ala²Gly substitution as the minimum modification needed to confer DPP-IV resistance. The resulting analog (h[Gly²]GLP-2; teduglutide) became the prototype for the GLP-2-receptor research-peptide class.[1]
Research framework
Within the gut-tropic research-peptide family, teduglutide is most directly compared with BPC-157 (a 15-mer derived from gastric juice studied in mucosal-integrity and angiogenesis assays) and KPV (an α-MSH C-terminal tripeptide studied in intestinal inflammation models). Teduglutide is the only member of this set that engages a defined Gαs-coupled receptor (GLP-2R) on the intestinal epithelium itself, supplying investigators with a tool that isolates GLP-2R-mediated mucosal-growth signaling from the broader cytokine, prostaglandin, and angiogenesis pathways activated by the gastric-juice peptides.[5][6]
“Preclinical Research Summary Foundational Studies StudyModelKey FindingsRef Drucker et al.”
References
- Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93(15):7911-7916.
- Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15(7):673-677.
- Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275(5):G911-G921.
- Cheeseman CI, Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol. 1996;271(3):G477-G482.
- Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96(4):1569-1573.
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.
- Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605.
- Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48(11):1289-1299.
- Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277(5):E937-E947.
- Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1):22-32.
- Prasad R, Alavi K, Schwartz MZ. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg. 2000;35(2):357-359.
- Yusta B, Holland D, Koehler JA, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009;137(3):986-996.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.